📣 VC round data is live. Check it out!

Nuvectis Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Nuvectis Pharma and similar public comparables like Akebia Therapeutics, REPLOID Group, Reig Jofré, Tiansheng Pharmaceutical and more.

Nuvectis Pharma Overview

About Nuvectis Pharma

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.


Founded

2020

HQ

United States

Employees

13

Financials (LTM)

Revenue: -
EBITDA: ($28M)

EV

$227M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Nuvectis Pharma Financials

Nuvectis Pharma reported last 12-month revenue of - and negative EBITDA of ($28M).

In the same LTM period, Nuvectis Pharma generated - in gross profit, ($28M) in EBITDA losses, and had net loss of ($28M).

Revenue (LTM)


Nuvectis Pharma P&L

In the most recent fiscal year, Nuvectis Pharma reported revenue of - and EBITDA of ($28M).

Nuvectis Pharma is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.

See analyst estimates for Nuvectis Pharma
LTMLast FY202320242025202620272028
EBITDA($28M)($28M)($23M)($20M)($28M)
Net Profit($28M)($26M)($22M)($19M)($26M)

Financial data powered by Morningstar, Inc.

Nuvectis Pharma Stock Performance

Nuvectis Pharma has current market cap of $253M, and enterprise value of $227M.

Market Cap Evolution


Nuvectis Pharma's stock price is $9.52.

Nuvectis Pharma share price decreased by 2.7% in the last 30 days, and increased by 45.6% in the last year.

Nuvectis Pharma has an EPS (earnings per share) of $-1.00.

See more trading valuation data for Nuvectis Pharma
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$227M$253M-2.3%-2.7%23.2%45.6%$-1.00

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Nuvectis Pharma Valuation Multiples

Nuvectis Pharma trades at (8.1x) EV/EBITDA.

See NTM and 2027E valuation multiples for Nuvectis Pharma

EV / Revenue (LTM)


Nuvectis Pharma Financial Valuation Multiples

As of June 3, 2026, Nuvectis Pharma has market cap of $253M and EV of $227M.

Nuvectis Pharma has a P/E ratio of (9.1x).

LTMLast FY202320242025202620272028
EV/EBITDA(8.1x)(8.2x)(9.9x)(11.5x)(8.2x)
EV/EBIT(8.4x)(8.2x)(9.9x)(11.5x)(8.2x)
P/E(9.1x)(9.6x)(11.3x)(13.3x)(9.6x)
EV/FCF-(14.2x)(14.3x)(18.6x)(14.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Nuvectis Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Nuvectis Pharma Margins & Growth Rates

Nuvectis Pharma grew EBITDA by 4% in the last fiscal year.

See estimated margins and future growth rates for Nuvectis Pharma

Nuvectis Pharma Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
EBITDA Growth4%(13%)39%4%
EBIT Growth(4%)(13%)39%(4%)
Net Profit Growth(1%)(15%)39%(1%)
FCF Growth-(23%)31%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Nuvectis Pharma Operational KPIs

Nuvectis Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.1M for the same period.

Access forward-looking KPIs for Nuvectis Pharma
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$2.1M

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Nuvectis Pharma Competitors

Nuvectis Pharma competitors include Akebia Therapeutics, REPLOID Group, Reig Jofré, Tiansheng Pharmaceutical, Macrogenics, Entrada Therapeutics, Anavex Life Sciences, AFT Pharmaceuticals, Tetratherix and Sensorion.

Most Nuvectis Pharma public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Akebia Therapeutics0.6x0.6x6.4x-
REPLOID Group42025.8x---
Reig Jofré0.9x0.9x9.3x9.6x
Tiansheng Pharmaceutical3.6x-25.6x-
Macrogenics0.9x1.0x(2.3x)-
Entrada Therapeutics8.9x9.9x(1.5x)(1.4x)
Anavex Life Sciences--(2.7x)-
AFT Pharmaceuticals1.8x1.8x16.6x15.9x

This data is available for Pro users. Sign up to see all Nuvectis Pharma competitors and their valuation data.

Start Free Trial

Nuvectis Pharma VC Funding History

Before going public, Nuvectis Pharma raised $15M in total equity funding, across 1 round.


Nuvectis Pharma Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Oct-21Series A-$15M-Nuvectis Pharma is a biopharmaceutical company developing precision oncology medicines, including NXP800, an HSF1 pathway inhibitor, and NXP900. In May 2021, the company raised $15.3 million in Series A funding from Sixth Element Capital and other investors. In August 2021, Nuvectis completed a $15 million Series A Preferred Stock financing and licensed exclusive worldwide rights to NXP800 from the CRT Pioneer Fund. A Phase 1a trial for NXP800 in advanced solid tumors began in December 2021. No funding round matching October 29, 2021, was identified, with the company reporting $5.7 million in cash and $9.6 million in R&D expenses for fiscal year 2021.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Nuvectis Pharma

When was Nuvectis Pharma founded?Nuvectis Pharma was founded in 2020.
Where is Nuvectis Pharma headquartered?Nuvectis Pharma is headquartered in United States.
How many employees does Nuvectis Pharma have?As of today, Nuvectis Pharma has over 13 employees.
Who is the CEO of Nuvectis Pharma?Nuvectis Pharma's CEO is Ron Bentsur.
Is Nuvectis Pharma publicly listed?Yes, Nuvectis Pharma is a public company listed on Nasdaq.
What is the stock symbol of Nuvectis Pharma?Nuvectis Pharma trades under NVCT ticker.
When did Nuvectis Pharma go public?Nuvectis Pharma went public in 2022.
Who are competitors of Nuvectis Pharma?Nuvectis Pharma main competitors include Akebia Therapeutics, REPLOID Group, Reig Jofré, Tiansheng Pharmaceutical, Macrogenics, Entrada Therapeutics, Anavex Life Sciences, AFT Pharmaceuticals, Tetratherix, Sensorion.
What is the current market cap of Nuvectis Pharma?Nuvectis Pharma's current market cap is $253M.
Is Nuvectis Pharma profitable?No, Nuvectis Pharma is not profitable.
What is the current EBITDA of Nuvectis Pharma?Nuvectis Pharma has negative EBITDA and is not profitable.
What is the current EV/EBITDA multiple of Nuvectis Pharma?Current EBITDA multiple of Nuvectis Pharma is (8.1x).
How many companies Nuvectis Pharma has acquired to date?Nuvectis Pharma hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Nuvectis Pharma has invested to date?Nuvectis Pharma hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Nuvectis Pharma

Lists including Nuvectis Pharma

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial